Paragon Advisors’s Amedisys AMED Stock Holding History

Paragon Advisors’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,079	Closed	-$1.08M	–	69
2021 Q1	$1.08M	Buy	4,079 +482	+13%	+$136K	0.59%	52
2020 Q4	$1.04M	Buy	+3,597	New	+$922K	0.56%	50

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paragon Advisors's AMED Position: Q2 2021 in Review

Paragon Advisors sold out of Amedisys (AMED) in Q2 2021, closing a stake of 4,079 shares — an estimated $1.08M sold.

Paragon Advisors first reported a position in AMED in Q4 2020 and held it in 2 quarters. The position peaked at $1.08M in Q1 2021. 375 funds tracked by Wall St. Rank hold AMED as of Q2 2021.

Paragon Advisors reported no remaining Amedisys position as of Q2 2021 after selling out during the quarter.
Paragon Advisors sold 4,079 Amedisys shares in Q2 2021, an estimated $1.08M.
Paragon Advisors first reported a position in Amedisys in Q4 2020 and held it in 2 quarters.
Paragon Advisors's Amedisys position peaked at $1.08M in Q1 2021.
375 funds tracked by Wall St. Rank held Amedisys as of Q2 2021.

Based on Paragon Advisors's 13F filing for Q2 2021, filed 9 Jul 2021.